Cancer – STUDY00002718: A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin Lymphoma

What is the goal of this study?

The goal of this industry-sponsored phase 1 study is to evaluate the safety and efficacy of JCAR017. 

Who can join the study?

This study is for children and young adults who:

• Have relapsed or refractory CD19+ acute lymphoblastic leukemia or non-Hodgkin lymphoma
• Are ages 0 to 25 years old

What will happen if my child takes part in this study?

If you choose to participate in this study, you may be asked to do the following:

• Consent and screening meeting
• Apheresis
• Lymphodepletion therapy (5-10 days prior to infusion)
• JCAR017 Infusion (day 1)
• Clinical visits on days 2, 3, 4, 7, 10, 14, 21, 28 and 56
• Long-term follow up visits around months 3, 6, 9, 12, 18 and 24

You can read about the study protocol on clinicaltrials.gov.

Who can I contact for more information?

For more information, call 206-987-2106 or send us an email.